- Viking Therapeutics (NasdaqCM: VKTX) started a new exploratory oral maintenance dosing study of obesity drug candidate VK2735.
- The firm is also testing additional VK2735 oral and subcutaneous dosing regimens aimed at treating metabolic disorders such as obesity.
- Management reported that both Phase 3 VANQUISH-1 and VANQUISH-2 obesity trials of VK2735 are now fully enrolled.
- The new VK2735 oral maintenance and dosing work is only one part of the broader story at Viking Therapeutics. Check out 4 warning signs (1 major) that Viking Therapeutics investors should know about.
Consider widening your watchlist to other healthcare stocks using 35 healthcare AI stocks.
Viking Therapeutics is a US biopharma developer focused on therapies for metabolic and endocrine disorders, so VK2735 sits at the center of its effort to build a pipeline in obesity care. The new oral maintenance study and fully enrolled late stage trials show how much of the current R&D agenda is concentrated in this therapy area.
VK2735 maintenance work sharpens the Viking Therapeutics obesity bet
For investors following Viking Therapeutics, the fresh maintenance dosing study reinforces the existing bull story that VK2735 could support long term obesity treatment across both injectable and oral routes. It leans directly into the Narrative catalysts around flexible dosing and extended treatment duration, while also underlining that the business is still a single program heavy bet with no revenue and rising R&D spend. The bear side of the story, centered on clinical and execution risk in large Phase 3 trials and the potential for further cash burn, remains fully in play rather than reduced.
See how these catalysts shape Viking Therapeutics' path to a $92.72 fair value.
The critical signpost from here is the first meaningful readout from the VANQUISH-1 or VANQUISH-2 Phase 3 programs, which are both 78 week trials. As those obesity studies move toward their main efficacy and safety data, the result will either support the current VK2735 centric Narrative or force a rethink on the long term revenue potential investors are assuming.
The overlooked question for Viking Therapeutics, what story do the next few years actually tell?
Analysts have mapped out where they think Viking Therapeutics could be a few years from now, and that picture goes far beyond today’s clinical headlines. See where analysts expect Viking Therapeutics to be in a few years.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com